The results showed that PLGA-PEG nanoparticles accumulated in the TAM-sufficient tumor by 7-fold higher than that in TAM-deficient tumor, indicating that CD44 may be an ideal target for imaging-guided TAM-oriented cancer immunotherapy (48). The gene discussed is CD44; the disease is cancer.